Skip to content

Study · Randomized controlled trial · 2003

5 results

The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth.

Drake WM, Carroll PV, Maher KT, Metcalfe KA, Camacho-Hübner C, Shaw NJ, Dunger DB, Cheetham TD, Savage MO, Monson JP

The Journal of clinical endocrinology and metabolism1 Apr 2003Cited by 59 (Europe PMC)

PMID12679453 (opens in a new tab)DOI10.1210/jc.2002-021541 (opens in a new tab)PepBankPUB-12679453
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adolescents with severe GH deficiency, the between-group difference in median bone mineral content change was marginally significant at 6 months (P = 0.085).

    In plain wordsIn adolescents with severe GH deficiency, the abstract called the six-month bone mineral content difference marginally significant (P = 0.085).

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeBone mineral content six-month comparison
    Study

    n: not reported in source

    Comparator
    discontinued GH
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.35 IU/kg x wk · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The differences in median change in BMC between the two groups at 6 and 12 months was marginally significant (P = 0.085 and 0.074, respectively).
    1 context sentence
    Summary · context
    In this United Kingdom multicenter study, 24 adolescents (13 males, mean age 17.0 +/- 1.4 yr, SD) with severe GHD were randomized to discontinue or continue GH (0.35 IU/kg x wk) at the completion of linear growth.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adolescents with severe GH deficiency, the between-group difference in median bone mineral content change was marginally significant at 12 months (P = 0.074).

    In plain wordsIn adolescents with severe GH deficiency, the abstract called the twelve-month bone mineral content difference marginally significant (P = 0.074).

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeBone mineral content twelve-month comparison
    Study

    n: not reported in source

    Comparator
    discontinued GH
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.35 IU/kg x wk · 1 yrAs given in this study (human).

    Source sentences

    Summary
    The differences in median change in BMC between the two groups at 6 and 12 months was marginally significant (P = 0.085 and 0.074, respectively).
    1 context sentence
    Summary · context
    In this United Kingdom multicenter study, 24 adolescents (13 males, mean age 17.0 +/- 1.4 yr, SD) with severe GHD were randomized to discontinue or continue GH (0.35 IU/kg x wk) at the completion of linear growth.
  3. 03HumanNon-randomized trialEfficacy outcome

    In adolescents with severe GH deficiency continuing GH, median bone mineral content increased 3.8% at 6 months (interquartile range 2.6-5.9; P < 0.001).

    In plain wordsIn adolescents with severe GH deficiency, bone mineral content increased from baseline during continued growth hormone treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseBone mineral content at six months
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.35 IU/kg x wk · 6 monthsAs given in this study (human).

    Measurements

    median change in whole body bone mineral content
    3.8%
    continued GH group at 6 months
    interquartile range of median BMC change
    2.6 to 5.9%
    continued GH group at 6 months

    Source sentences

    Summary
    In patients who continued GH (GH+), median BMC increased by 3.8% (interquartile range, 2.6, 5.9, P < 0.001) at 6 months; and by 6.0% (3.7-9.1, P < 0.001) at 12 months.
    1 context sentence
    Summary · context
    In this United Kingdom multicenter study, 24 adolescents (13 males, mean age 17.0 +/- 1.4 yr, SD) with severe GHD were randomized to discontinue or continue GH (0.35 IU/kg x wk) at the completion of linear growth.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adolescents with severe GH deficiency continuing GH, median bone mineral content increased 6.0% at 12 months (interquartile range 3.7-9.1; P < 0.001).

    In plain wordsIn adolescents with severe GH deficiency, bone mineral content increased from baseline during continued growth hormone treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseBone mineral content at twelve months
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.35 IU/kg x wk · 1 yrAs given in this study (human).

    Measurements

    median change in whole body bone mineral content
    6%
    continued GH group at 12 months
    interquartile range of median BMC change
    3.7 to 9.1%
    continued GH group at 12 months

    Source sentences

    Summary
    In patients who continued GH (GH+), median BMC increased by 3.8% (interquartile range, 2.6, 5.9, P < 0.001) at 6 months; and by 6.0% (3.7-9.1, P < 0.001) at 12 months.
    1 context sentence
    Summary · context
    In this United Kingdom multicenter study, 24 adolescents (13 males, mean age 17.0 +/- 1.4 yr, SD) with severe GHD were randomized to discontinue or continue GH (0.35 IU/kg x wk) at the completion of linear growth.
  5. 05HumanNon-randomized trialEfficacy outcome

    In adolescents with severe GH deficiency continuing GH, lumbar spine bone mineral density increased by 4.7 (95% CI 1.0-8.2) at 12 months (P = 0.01).

    In plain wordsIn adolescents with severe GH deficiency, lumbar spine bone mineral density increased from baseline during continued growth hormone treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLumbar spine bone mineral density
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.35 IU/kg x wk · 1 yrAs given in this study (human).

    Measurements

    mean change in lumbar spine bone mineral density
    4.7 not stated
    continued GH group at 12 months
    95% CI of mean change in lumbar spine bone mineral density
    1 to 8.2 not stated
    continued GH group at 12 months

    Source sentences

    Summary
    Mean lumbar spine bone mineral density increased by 4.7 (95% confidence interval, 1.0, 8.2) at 12 months in patients continuing GH (P = 0.01),
    1 context sentence
    Summary · context
    In this United Kingdom multicenter study, 24 adolescents (13 males, mean age 17.0 +/- 1.4 yr, SD) with severe GHD were randomized to discontinue or continue GH (0.35 IU/kg x wk) at the completion of linear growth.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.